Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C134 Intratumoral Injection in Recurrent Malignant Glioma
NCT06614855Phase 1Active, not recruiting
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C134 in glioblastoma (GBM), astrocytoma and Gliosarcoma (GS). Primary endpoint: Safety of a two dose intracerebral injection of C134 virus at 12 months. Started Jun 2025; status: active, not recruiting.
02
Drugs
C134
03
Conditions
glioblastoma (GBM)astrocytomaGliosarcoma (GS)
Beyond the preview
Go deeper on NCT06614855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06614855.